![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC25A25 |
Gene summary for SLC25A25 |
![]() |
Gene information | Species | Human | Gene symbol | SLC25A25 | Gene ID | 114789 |
Gene name | solute carrier family 25 member 25 | |
Gene Alias | MCSC | |
Cytomap | 9q34.11 | |
Gene Type | protein-coding | GO ID | GO:0001654 | UniProtAcc | Q6KCM7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
114789 | SLC25A25 | C57 | Human | Oral cavity | OSCC | 5.55e-09 | 4.67e-01 | 0.1679 |
114789 | SLC25A25 | C06 | Human | Oral cavity | OSCC | 1.85e-02 | 2.96e-01 | 0.2699 |
114789 | SLC25A25 | C09 | Human | Oral cavity | OSCC | 3.07e-13 | 4.01e-01 | 0.1431 |
114789 | SLC25A25 | LN22 | Human | Oral cavity | OSCC | 6.14e-04 | 6.70e-01 | 0.1733 |
114789 | SLC25A25 | LN46 | Human | Oral cavity | OSCC | 2.15e-24 | 1.26e+00 | 0.1666 |
114789 | SLC25A25 | LP15 | Human | Oral cavity | LP | 5.26e-05 | 1.06e+00 | 0.2174 |
114789 | SLC25A25 | EOLP-1 | Human | Oral cavity | EOLP | 1.71e-08 | 3.44e-01 | -0.0202 |
114789 | SLC25A25 | NEOLP-1 | Human | Oral cavity | NEOLP | 9.46e-03 | 2.95e-01 | -0.0194 |
114789 | SLC25A25 | SYSMH3 | Human | Oral cavity | OSCC | 5.43e-05 | 1.09e-01 | 0.2442 |
114789 | SLC25A25 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 1.09e-02 | -2.38e-01 | 0.02 |
114789 | SLC25A25 | male-WTA | Human | Thyroid | PTC | 2.22e-03 | -1.67e-01 | 0.1037 |
114789 | SLC25A25 | PTC01 | Human | Thyroid | PTC | 1.03e-05 | -1.54e-01 | 0.1899 |
114789 | SLC25A25 | PTC04 | Human | Thyroid | PTC | 1.57e-04 | -7.75e-02 | 0.1927 |
114789 | SLC25A25 | PTC06 | Human | Thyroid | PTC | 1.64e-02 | 9.88e-02 | 0.2057 |
114789 | SLC25A25 | PTC07 | Human | Thyroid | PTC | 9.77e-08 | -7.25e-02 | 0.2044 |
114789 | SLC25A25 | ATC12 | Human | Thyroid | ATC | 7.44e-06 | -1.69e-01 | 0.34 |
114789 | SLC25A25 | ATC13 | Human | Thyroid | ATC | 1.79e-08 | -1.19e-01 | 0.34 |
114789 | SLC25A25 | ATC4 | Human | Thyroid | ATC | 5.17e-06 | -1.49e-01 | 0.34 |
114789 | SLC25A25 | ATC5 | Human | Thyroid | ATC | 4.82e-05 | -9.88e-02 | 0.34 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006091110 | Esophagus | ESCC | generation of precursor metabolites and energy | 331/8552 | 490/18723 | 3.86e-23 | 8.45e-21 | 331 |
GO:0045333110 | Esophagus | ESCC | cellular respiration | 173/8552 | 230/18723 | 4.53e-20 | 5.99e-18 | 173 |
GO:0015980110 | Esophagus | ESCC | energy derivation by oxidation of organic compounds | 220/8552 | 318/18723 | 1.20e-17 | 1.09e-15 | 220 |
GO:001593117 | Esophagus | ESCC | nucleobase-containing compound transport | 162/8552 | 222/18723 | 9.87e-17 | 7.93e-15 | 162 |
GO:0046034111 | Esophagus | ESCC | ATP metabolic process | 189/8552 | 277/18723 | 1.99e-14 | 1.04e-12 | 189 |
GO:0031667111 | Esophagus | ESCC | response to nutrient levels | 289/8552 | 474/18723 | 9.25e-12 | 3.47e-10 | 289 |
GO:00352647 | Esophagus | ESCC | multicellular organism growth | 80/8552 | 132/18723 | 3.84e-04 | 2.22e-03 | 80 |
GO:000609118 | Oral cavity | OSCC | generation of precursor metabolites and energy | 286/7305 | 490/18723 | 1.45e-18 | 1.71e-16 | 286 |
GO:001593114 | Oral cavity | OSCC | nucleobase-containing compound transport | 150/7305 | 222/18723 | 4.86e-18 | 5.04e-16 | 150 |
GO:004533318 | Oral cavity | OSCC | cellular respiration | 153/7305 | 230/18723 | 2.07e-17 | 1.87e-15 | 153 |
GO:001598018 | Oral cavity | OSCC | energy derivation by oxidation of organic compounds | 190/7305 | 318/18723 | 4.10e-14 | 2.26e-12 | 190 |
GO:004603420 | Oral cavity | OSCC | ATP metabolic process | 166/7305 | 277/18723 | 1.16e-12 | 5.12e-11 | 166 |
GO:003166720 | Oral cavity | OSCC | response to nutrient levels | 245/7305 | 474/18723 | 1.02e-08 | 2.10e-07 | 245 |
GO:19012642 | Oral cavity | OSCC | carbohydrate derivative transport | 44/7305 | 80/18723 | 2.67e-03 | 1.16e-02 | 44 |
GO:00148233 | Oral cavity | OSCC | response to activity | 41/7305 | 76/18723 | 5.78e-03 | 2.22e-02 | 41 |
GO:00352646 | Oral cavity | OSCC | multicellular organism growth | 65/7305 | 132/18723 | 1.06e-02 | 3.60e-02 | 65 |
GO:004533319 | Oral cavity | LP | cellular respiration | 124/4623 | 230/18723 | 1.35e-21 | 3.38e-19 | 124 |
GO:000609119 | Oral cavity | LP | generation of precursor metabolites and energy | 214/4623 | 490/18723 | 1.12e-20 | 2.60e-18 | 214 |
GO:001598019 | Oral cavity | LP | energy derivation by oxidation of organic compounds | 145/4623 | 318/18723 | 2.44e-16 | 3.64e-14 | 145 |
GO:0046034110 | Oral cavity | LP | ATP metabolic process | 128/4623 | 277/18723 | 3.95e-15 | 5.38e-13 | 128 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC25A25 | SNV | Missense_Mutation | c.385N>A | p.Asp129Asn | p.D129N | Q6KCM7 | protein_coding | deleterious(0) | possibly_damaging(0.84) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
SLC25A25 | SNV | Missense_Mutation | c.1088N>T | p.Ser363Leu | p.S363L | Q6KCM7 | protein_coding | deleterious(0.01) | benign(0.029) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
SLC25A25 | SNV | Missense_Mutation | rs753341608 | c.1358C>T | p.Ala453Val | p.A453V | Q6KCM7 | protein_coding | deleterious(0.03) | probably_damaging(0.923) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC25A25 | SNV | Missense_Mutation | rs772416779 | c.1421N>A | p.Arg474Gln | p.R474Q | Q6KCM7 | protein_coding | tolerated(0.7) | benign(0.007) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC25A25 | SNV | Missense_Mutation | c.1470N>T | p.Met490Ile | p.M490I | Q6KCM7 | protein_coding | tolerated(0.29) | benign(0.061) | TCGA-AA-3695-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
SLC25A25 | SNV | Missense_Mutation | c.61G>A | p.Ala21Thr | p.A21T | Q6KCM7 | protein_coding | tolerated_low_confidence(0.46) | benign(0) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC25A25 | SNV | Missense_Mutation | rs765220171 | c.733N>A | p.Val245Ile | p.V245I | Q6KCM7 | protein_coding | deleterious(0.05) | possibly_damaging(0.471) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SLC25A25 | SNV | Missense_Mutation | novel | c.274N>A | p.Ala92Thr | p.A92T | Q6KCM7 | protein_coding | tolerated(0.37) | benign(0.021) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC25A25 | SNV | Missense_Mutation | novel | c.1323N>A | p.Ser441Arg | p.S441R | Q6KCM7 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC25A25 | SNV | Missense_Mutation | novel | c.1016N>G | p.Ile339Ser | p.I339S | Q6KCM7 | protein_coding | tolerated(0.05) | possibly_damaging(0.454) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |